This comprehensive review highlights the risk factors, clinical presentation, pathophysiology, diagnosis, and treatment of heparin-induced thrombocytopenia.
Clinical vigilance is crucial for the recognition, diagnosis, and treatment of heparin-induced thrombocytopenia to reduce morbidity and mortality, particularly in patients undergoing cardiopulmonary bypass or catheterization.
Heparin-induced thrombocytopenia is a profoundly dangerous, potentially lethal, immunologically mediated adverse drug reaction to unfractionated heparin or, less commonly, to low-molecular weight heparin. In this comprehensive review, the authors highlight heparin-induced thrombocytopenia's risk factors, clinical presentation, pathophysiology, diagnostic principles, and treatment. The authors place special emphasis on the management of patients requiring procedures using cardiopulmonary bypass or interventions in the catheterization laboratory. Clinical vigilance of this disease process is important to ensure its recognition, diagnosis, and treatment. Misdiagnosis of the syndrome, as well as misunderstanding of the disease process, continues to contribute to its morbidity and mortality.
Salter et al. (Sun,) conducted a review in Heparin-induced thrombocytopenia. This comprehensive review highlights the risk factors, clinical presentation, pathophysiology, diagnosis, and treatment of heparin-induced thrombocytopenia.